Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Active Biotech AB's enterprise value is €6.42 Mil.
Active Biotech AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-3.21 Mil. Therefore, Active Biotech AB's EV-to-EBITDA for today is -2.00.
The historical rank and industry rank for Active Biotech AB's EV-to-EBITDA or its related term are showing as below:
FRA:BTP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -36.58 Med: -5.74 Max: 1.09
Current: -2.04
During the past 13 years, the highest EV-to-EBITDA of Active Biotech AB was 1.09. The lowest was -36.58. And the median was -5.74.
FRA:BTP's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs FRA:BTP: -2.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Active Biotech AB (FRA:BTP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Active Biotech AB's PE Ratio (TTM) for today is calculated as:
Active Biotech AB's share price for today is €0.4455.
Active Biotech AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.164.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Active Biotech AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BTP vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Active Biotech AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's EV-to-EBITDA falls into.
Active Biotech AB's current Enterprise Value is €6.42 Mil.
Active Biotech AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB (FRA:BTP) has a EV-to-EBITDA of -2.00 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Active Biotech AB. According to the industry distribution chart, Active Biotech AB ranks #999999 out of 402 companies in the Biotechnology industry.
Is Active Biotech AB's EV-to-EBITDA too high?
Active Biotech AB's current EV-to-EBITDA is -2.00. Based on the distribution chart, Active Biotech AB ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Active Biotech AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #999999 out of 402 companies for EV-to-EBITDA. This places Active Biotech AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Active Biotech AB. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Active Biotech AB's current EV-to-EBITDA is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.45 — trading 242.7% above its estimated fair value. The current EV-to-EBITDA is -2.00. Active Biotech AB's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current EV-to-EBITDA is -2.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Active Biotech AB (FRA:BTP) Overvalued in 2026?
Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued.
The current stock price of €0.45 is trading 242.7% above its estimated GF Value™ of €0.13.
GuruFocus considers Active Biotech AB to be Significantly Overvalued.
Key valuation signals for FRA:BTP:
EV-to-EBITDA: -2.00
GF Value™: €0.13 vs. price of €0.45 (242.7% above fair value)
No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
34GF Score
Get the complete analysis for FRA:BTP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BTP has been successfully added to your 
